AUG 7, 2026 · PHASE 1 TRIAL
A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations
ClinicalTrials.gov
Phase 1 pharmacokinetic study of a new drug formulation in a completed trial; results not yet reported in this registry record.
Reported
Planned enrollment349
PhasePhase 1
Primary outcome measure 1AUCinf of AMG 133, up to Day 120